Epidemiological Characteristics and Prediction System of Acute Respiratory Distress Syndrome

China-Japan Friendship Hospital

Status: Invitation-only

Conditions: Acute Respiratory Distress Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT06069466

2023-NHLHCRF-YYPP-TS-04

Details and patient eligibility

About

This project intends to adopt the multicenter prospective real-world study method to conduct a preliminary study on the incidence, grading, risk factors, respiratory support strategies, in-hospital mortality, 3-month mortality, 6-month mortality, 1-year mortality, quality of life, lung function and limb function recovery, cognitive function, return to work and other conditions of ARDS patients in RICU. By collecting 1,000 patients, a clinical database related to ARDS in China was established to provide essential data and ideas for promoting standardized diagnosis and treatment technology for ARDS patients and further clinical intervention research. At the same time, ARDS biobank was established in China-Japan Hospital and Xiangya Hospital to realize the integration of clinical data and sample resources, and the prediction model of ARDS survival and complications of tuberculosis clinical data and biological samples was established by using big data and AI technology.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• New or worsening respiratory symptoms less than 7 days after the acute blow.
• CT/X-ray: Double lung infiltration that cannot be fully explained by pleural effusion, lobar/whole atelectasis, and nodule.
• Respiratory failure that cannot be explained by heart failure or fluid overload
• After 15min assisted ventilation (PEEP or CPAP ≥ 5cmH2O) or HFNC with flow≥30L/min, PaO2/FiO2≤300mmHg
• Classification of ARDS: mild (200mmHg < PaO2/FIO2 ≤ 300mmHg), moderate (100mmHg < PaO2/FIO2 ≤ 200mmHg), and severe (PaO2/FIO2 ≤ 100mmHg) and 4 ancillary variables for severe ARDS

Exclusion criteria

• younger than 18 years old
• Patients or family members refused to participate in the study

Trial design

1,000 participants in 1 patient group

ARDS patient